multi target TKI

Description Results NMA

PFS 0.71 [0.53; 0.96] Demonstrated

SAE 2.00 [1.57; 2.55]

OS 0.78 [0.57; 1.07]

daily letrozole (2.5 mg orally) plus lapatinib (1,500 mg orally) (n=1286)

vs.

letrozole (n=0)

double-blind

Parallel groups

Sample size: 1286/0

Primary endpoint:

FU duration:

SAE 1.65 [1.16; 2.35]

OS 0.86 [0.69; 1.08]

PFS 0.90 [0.75; 1.08]

first-line therapy with paclitaxel 175 mg/m(2) every 3 weeks plus lapatinib 1,500 mg/d (n=579)

vs.

paclitaxel (n=0)

double-blind

Parallel groups

Sample size: 579/0

Primary endpoint: TTP

FU duration:

PFS 0.64 [0.44; 0.93]

OS 1.01 [0.71; 1.44]

PFS 0.58 [0.41; 0.82]

OS 0.86 [0.61; 1.22]

sorafenib (400 mg, twice daily) (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

- or second-line capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle with sorafenib 400 mg orally twice a day (n=-9)

vs.

capecitabine alone (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

OS 1.02 [0.71; 1.46]

PFS 0.79 [0.56; 1.11]

paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) plus sorafenib (400mg, orally, twice daily) (n=-9)

vs.

paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.67 [0.54; 0.81]

axitinib (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

OS 0.67 [0.51; 0.89]

PFS 0.58 [0.45; 0.75]

cabozantinib at a dose of 60 mg daily (n=330)

vs.

everolimus at a dose of 10 mg daily (n=328)

open-label

Parallel groups

Sample size: 330/328

Primary endpoint: PFS

FU duration:

phase 3

PFS 0.66 [0.46; 0.95] median 8.2 mo vs. 5.6 mo

cabozantinib (60 mg once per day) (n=79)

vs.

sunitinib (50 mg once per day; 4 weeks on, 2 weeks off). (n=78)

open-label

Parallel groups

Sample size: 79/78

Primary endpoint: PFS

FU duration:

phase 2

PFS 0.86 [0.72; 1.03]

dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) (n=284)

vs.

sorafenib (400 mg orally twice daily) (n=286)

open-label

Sample size: 284/286

Primary endpoint:

FU duration:

PFS 0.46 [0.34; 0.62]

PFS 0.46 [0.34; 0.62]

OS 0.91 [0.71; 1.16]

OS 0.91 [0.76; 1.08]

PFS 1.05 [0.90; 1.22]

pazopanib (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

(n=290)

vs.

(n=145)

Sample size: 290/145

Primary endpoint: PFS

FU duration:

continuous dose of pazopanib (800 mg once daily) (n=557)

vs.

sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment) (n=553)

Parallel groups

Sample size: 557/553

Primary endpoint: PFS

FU duration:

PFS 0.88 [0.61; 1.27]

PFS 0.44 [0.35; 0.55]

OS 0.88 [0.74; 1.04]

oral sorafenib 400 mg twice daily (n=97)

vs.

subcutaneous IFN--2a 9 million U three times weekly (n=92)

Parallel groups

Sample size: 97/92

Primary endpoint:

FU duration:

phase 2

continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) (n=451)

vs.

placebo (n=452)

Parallel groups

Sample size: 451/452

Primary endpoint: OS

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.42 [0.32; 0.55]

OS 0.82 [0.67; 1.00]

repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) (n=375)

vs.

interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). (n=375)

Sample size: 375/375

Primary endpoint: PFS

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.80 [0.64; 0.99]

OS 1.25 [0.95; 1.63]

tivozanib (n=260)

vs.

sorafenib (n=257)

Sample size: 260/257

Primary endpoint: PFS

FU duration: